ArticleNPJ biofilms and microbiomes2024
Christensenella minuta protects and restores intestinal barrier in a colitis mouse model by regulating inflammation.
Article in NPJ biofilms and microbiomes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Gut microbiota responses to bariatric surgery are associated with metabolic outcomes and type 2 diabetes remission.Nature metabolism · 2026Trial
- EB1010, a putative Christensenellaceae-derived microbial peptide, exhibits anti-inflammatory activity and therapeutic potential in ulcerative colitis.Gut microbes · 2026Article
- Dietary Yeast Hydrolysate Alters Serum Metabolic Profiles and Selected Fecal Bacterial Taxa in Lactating Dezhou Jennies.Microorganisms · 2026Article
- Christensenella minuta DSM 22607 and Food Restriction Manage Age-Related Disorders In Vivo.Probiotics and antimicrobial proteins · 2026Article
- Does Intrarectal Administration ofNutrients · 2026Article
- Temporal intervention of yeast β-glucan and ellagic acid drives low-inflammatory trained immunity phenotype.NPJ science of food · 2026Article
- Amelioration of colitis through restored gut ecology using Christensenella intestinihominis AF73-05CM02 as a probiotic in mice.Communications biology · 2026Article
- Article
- Discovery and characterization of Christensenella hongkongensis as a novel bacterium in the adenoma-carcinoma progression.Journal of translational medicine · 2026Article
- Mechanistic Links Between the Gut Microbiome and Longevity Therapeutics.Biomedicines · 2026Review
- Cedrol ameliorates ulcerative colitisWorld journal of gastroenterology · 2026Article
- Potential and Challenges ofFoods (Basel, Switzerland) · 2025Review
- Clinical translation of microbiome research.Nature medicine · 2025Review
- The role and challenges of intratumoral microbiota in colorectal cancer immunotherapy.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Christensenella minuta DSM 22607 has recently been suggested as a potential microbiome-based therapy for inflammatory bowel disease (IBD) because it displays strong anti-inflammatory effects both in vitro and in vivo. Here, we aimed to decipher the mechanism(s) underlying the DSM 22607-mediated beneficial effects on the host in a mouse model of chemically induced acute colitis. We observed that C. minuta plays a key role in the preservation of the epithelial barrier and the management of DNBS-induced inflammation by inhibiting interleukin (IL)-33 and Tumor necrosis factor receptor superfamily member 8 (Tnfrsf8) gene expression. We also showed that DSM 22607 abundance was positively correlated with Akkermansia sp. and Dubosiella sp. and modulated microbial metabolites in the cecum. These results offer new insights into the biological and molecular mechanisms underlying the beneficial effects of C. minuta DSM 22607 by protecting the intestinal barrier integrity and regulating inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.